Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Retained Earnings (2016 - 2025)

Immucell's Retained Earnings history spans 16 years, with the latest figure at -$15.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 7.34% year-over-year to -$15.2 million; the TTM value through Dec 2025 reached -$15.2 million, down 7.34%, while the annual FY2025 figure was -$15.2 million, 7.34% down from the prior year.
  • Retained Earnings reached -$15.2 million in Q4 2025 per ICCC's latest filing, down from -$12.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$3.2 million in Q1 2022 to a low of -$15.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$9.1 million, with a median of -$10.4 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: rose 21.36% in 2022, then tumbled 165.01% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$3.7 million in 2021, then tumbled by 66.7% to -$6.2 million in 2022, then tumbled by 92.65% to -$12.0 million in 2023, then dropped by 17.96% to -$14.2 million in 2024, then decreased by 7.34% to -$15.2 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Retained Earnings are -$15.2 million (Q4 2025), -$12.4 million (Q3 2025), and -$12.2 million (Q2 2025).